Literature DB >> 32162184

An update on familial nonmedullary thyroid cancer.

Sabrine A Ammar1, Wilson M Alobuia1, Electron Kebebew2.   

Abstract

Familial nonmedullary thyroid cancer (FNMTC) constitutes 3-9% of all thyroid cancer cases. FNMTC is divided into two groups: syndromic and nonsyndromic. Nonsyndromic FNMTC is more common as compared with syndromic FNMTC. In syndromic FNMTC, patients are at risk of nonmedullary thyroid cancer (NMTC) and other tumors, and the susceptibility genes are known. In nonsyndromic FNMTC, NMTC is the major feature of the disease and occurs in isolation with an autosomal dominant pattern of inheritance and variable penetrance. New data have emerged on the genetics, clinical characteristics, and outcomes of patients with FNMTC that may have clinical relevance in the management of patients. In this review, we focus on newly characterized syndromic FNMTC entities, criteria for screening and surveillance of nonsyndromic FNMTC, and the classification of nonsyndromic FNMTC as well as the genetic background and heterogeneity of nonsyndromic FNMTC.

Entities:  

Keywords:  Familial; Nonmedullary thyroid cancer; Nonsyndromic; Papillary thyroid cancer; Syndromic

Mesh:

Year:  2020        PMID: 32162184     DOI: 10.1007/s12020-020-02250-3

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  45 in total

1.  On the prevalence of familial nonmedullary thyroid cancer in multiply affected kindreds.

Authors:  N David Charkes
Journal:  Thyroid       Date:  2006-02       Impact factor: 6.568

Review 2.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

3.  Prevalence, clinicopathologic features, and somatic genetic mutation profile in familial versus sporadic nonmedullary thyroid cancer.

Authors:  Willieford Moses; Julie Weng; Electron Kebebew
Journal:  Thyroid       Date:  2010-12-29       Impact factor: 6.568

4.  Results of Screening in Familial Non-Medullary Thyroid Cancer.

Authors:  Joanna Klubo-Gwiezdzinska; Lily Yang; Roxanne Merkel; Dhaval Patel; Naris Nilubol; Maria J Merino; Monica Skarulis; Samira M Sadowski; Electron Kebebew
Journal:  Thyroid       Date:  2017-07-19       Impact factor: 6.568

Review 5.  Screening for differentiated thyroid cancer in selected populations.

Authors:  Livia Lamartina; Giorgio Grani; Cosimo Durante; Sebastiano Filetti; David S Cooper
Journal:  Lancet Diabetes Endocrinol       Date:  2019-10-04       Impact factor: 32.069

Review 6.  Familial non-medullary thyroid cancer: unraveling the genetic maze.

Authors:  Samantha Peiling Yang; Joanne Ngeow
Journal:  Endocr Relat Cancer       Date:  2016-11-02       Impact factor: 5.678

7.  Familial papillary thyroid carcinoma: genetics, criteria for diagnosis, clinical features, and surgical treatment.

Authors:  T J Musholt; P B Musholt; T Petrich; G Oetting; W H Knapp; J Klempnauer
Journal:  World J Surg       Date:  2000-11       Impact factor: 3.352

Review 8.  Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer.

Authors:  Menno R Vriens; Insoo Suh; Willieford Moses; Electron Kebebew
Journal:  Thyroid       Date:  2009-12       Impact factor: 6.568

9.  Family Screening in Familial Papillary Carcinoma: The Early Detection of Thyroid Disease.

Authors:  Antonio Ríos; J M Rodríguez; D Navas; A Cepero; N M Torregrosa; M D Balsalobre; P Parrilla
Journal:  Ann Surg Oncol       Date:  2016-03-28       Impact factor: 5.344

10.  Prospective screening in familial nonmedullary thyroid cancer.

Authors:  Samira M Sadowski; Mei He; Krisana Gesuwan; Neelam Gulati; Francesco Celi; Maria J Merino; Naris Nilubol; Electron Kebebew
Journal:  Surgery       Date:  2013-08-23       Impact factor: 3.982

View more
  3 in total

1.  Comparison Between Clinicopathological Characteristics, BRAF V600E and TERT Promoter Mutation of Familial Non-Medullary Thyroid Carcinomas, and Sporadic Case.

Authors:  Tian Yang; Longsheng Huang; Chang Chen; Han Luo; Yong Jiang
Journal:  Front Oncol       Date:  2021-12-01       Impact factor: 6.244

2.  Risk of Second Malignant Neoplasm in Familial Non-Medullary Thyroid Cancer Patients.

Authors:  Marco Capezzone; Alfonso Sagnella; Silvia Cantara; Noemi Fralassi; Fabio Maino; Raffaella Forleo; Lucia Brilli; Tania Pilli; Alessandra Cartocci; Maria Grazia Castagna
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-04       Impact factor: 5.555

3.  Identification of NID1 as a novel candidate susceptibility gene for familial non-medullary thyroid carcinoma using whole-exome sequencing.

Authors:  Luis Eduardo Barbalho de Mello; Thaise Nayane Ribeiro Carneiro; Aline Neves Araujo; Camila Xavier Alves; Pedro Alexandre Favoretto Galante; Vanessa Candiotti Buzatto; Maria das Graças de Almeida; Karina Marques Vermeulen-Serpa; Sancha Helena de Lima Vale; Fernando José de Pinto Paiva; José Brandão-Neto; Janete Maria Cerutti
Journal:  Endocr Connect       Date:  2022-01-31       Impact factor: 3.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.